Table 1.

Available anti-tubulin agents with their years of approval, main indications, dose ranges and types of therapy (monotherapy, combination partners)

Drug	Main indications	Dose	Combinations
Vinblastine 1961*	Hodgkin’s disease, non-Hodgkin lymphoma, histiocytic lymphoma, mycosis fungoides, testis, Kaposi’s sarcoma, choriocarcinoma, breast, kidney	3.7 mg/m2-18.5 mg/m2	Monotherapy, mechlorethamine, doxorubicin, vincristine, bleomycin, etoposide, dacarbazine, brentuximab, cisplatin, ifosfamide, methotrexate, mitomycine
Vincristine 1963*	Leukemias, lymphomas, myeloma, breast, lung, head & neck, sarcomas, Wilms’ tumor, neuroblastoma, retinoblastoma, medulloblastoma,	0.8 mg/m2-2 mg	Monotherapy, doxorubicin, carboplatin mechlorethamine, vinblastine, bleomycin, etoposide, cyclophosphamide, procarbazine, topotecan, dactinomycin, leucovorin, actinomycin D
Vindesine 1982***	ALL, CML, melanoma, breast	3 mg/m2-4 mg/m2	Monotherapy, cisplatin
Vinorelbine 1994*	NSCLC, Hodgkin’s disease, non-Hodgkin lymphoma, rhabdomyosarcoma, Wilm’s tumor, neuroblastoma	25 mg/m2-30 mg/m2	Monotherapy, cisplatin
Vinflunine 2009**	Urothelial carcinoma	280 mg/m2-320 mg/m2	Monotherapy
Vincristine Liposomal 2012*	Philadelphia chromosome-negative ALL	2.25 mg/m2	Monotherapy
Paclitaxel 1992*	Ovarian, breast, lung, gastric, Kaposi’s sarcoma	100 mg/m2-210 mg/m2	Monotherapy, cisplatin, doxorubicin
Docetaxel 1996*	Breast, lung, prostate, gastric, head & neck	75 mg/m2-100 mg/m2	Monotherapy, cyclophosphamide, cisplatin, 5-fluorouracil
Nab-Paclitaxel 2005*	Breast, lung, pancreas	100 mg/m2-260 mg/m2	Monotherapy, carboplatin, gemcitabine
Cabazitaxel 2010*	Prostate	20 mg/m2-25 mg/m2	Monotherapy
Ixabepilone 2007*	Breast	40 mg/m2	Capecitabine

Anti-tubulin agents first approved by FDA (*), EMA (**) or in other countries (***). ALL: acute lymphoblastic leukemia; CML: chronic myelogenous leukemia; NSCLC: non-small-cell lung carcinoma